Palo Alto, California 94304


The investigators are testing treatment with low-dose naltrexone (LDN) for symptom relief of complex regional pain syndrome (CRPS). Study participants will be randomly assigned to receive either LDN or placebo for a period of several weeks. During this period participants will be asked to come to several visits, which will include sensory testing, physical assessments, and questionnaires.


Inclusion Criteria: - Upper and/or lower extremity CRPS - On stable treatment for 3 months - CRPS for at least 1 year - Meet the Budapest criteria for CRPS at time of the study. Exclusion Criteria: - Any known allergy to naltrexone or naloxone - Use of prescription opioid analgesics or illegal opioid use - Current of planned pregnancy.



Primary Contact:

Principal Investigator
Sean Mackey, MD, PhD
Stanford University

Maria L Adelus
Phone: (650) 724-9320

Backup Contact:


Location Contact:

Palo Alto, California 94304
United States

Maria L Adelus
Phone: 408-386-2143

Site Status: Recruiting

Data Source:

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.